Volume 1.39 | Oct 15

Prostate Cell News 1.39, October 15, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe




Interested in recruiting talented individuals? Post your career opportunities in Prostate Cell News at no cost. Contact us at [email protected]


Abiraterone Acetate Improves Survival in Metastatic Castration-Resistant Prostate Cancer: Phase III Results
Patients with metastatic castration-resistant prostate cancer who have progressed after chemotherapy live significantly longer if treated with the drug abiraterone acetate compared to placebo, the results of a large Phase III clinical trial confirm. [Press release from the European Society for Medical Oncology (ESMO) discussing data presented at the 35th ESMO Congress in Milan]

Popular Prostate Cancer Treatment Associated with Bone Decay
Using novel technology allowing “virtual bone biopsies” researchers have found that a common treatment for prostate cancer called androgen deprivation therapy is associated with structural decay of cortical and trabecular bone. [Press release from EurekAlert! discussing online prepublication in the Journal of Clinical Endocrinology and Metabolism]

Urine Protein Could Pave Way for New Prostate Cancer Test
Scientists have shown that a protein in urine could be a powerful indicator of prostate cancer risk. [Press release from Cancer Research UK discussing online prepublication in PLoS ONE]

Watch Procedure Now  
Use ALDEFLUOR® to Detect Prostate Precursor Cells
by STEMCELL Technologies

CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)


Tuberous Sclerosis Complex 1: An Epithelial Tumor Suppressor Essential to Prevent Spontaneous Prostate Cancer in Aged Mice
Here, researchers engineered constitutive mammalian target of rapamycin complex 1 (mTORC1) activation in prostate epithelium by a conditional genetic deletion of tuberous sclerosis complex 1, a potent negative regulator of mTORC1 signaling. [Cancer Res]

A Functional Variant in NKX3.1 Associated With Prostate Cancer Susceptibility Down-Regulates NKX3.1 Expression
The results suggest that the functional variant rs11781886 in the 5′-UTR of NKX3.1 can affect its transcription by altering the binding affinity of a transcriptional factor Sp1, and might result in prostate cancer susceptibility by lowering expression of NKX3.1 in the prostate. [Hum Mol Genet]

Mineralized Human Primary Osteoblast Matrices as a Model System to Analyse Interactions of Prostate Cancer Cells with the Bone Microenvironment
Researchers show that growth of prostate cancer cells on matrices produced by primary human osteoblasts mimics key features of prostate cancer bone metastases and thus is a suitable model system to study the tumor/bone micro-environment interaction in this disease. [Biomaterials]

Sulforaphane Increases Drug-Mediated Cytotoxicity Toward Cancer Stem-Like Cells of Pancreas and Prostate
The data suggest that the broccoli compound sulforaphane increases the effectiveness of various cytotoxic drugs against cancer stem cells without inducing additional toxicity in mice. [Mol Ther]

Docetaxel Loaded Oleic Acid-Coated Hydroxyapatite Nanoparticles Enhance the Docetaxel-Induced Apoptosis Through Activation of Caspase-2 in Androgen Independent Prostate Cancer Cells
In the present study, researchers investigated the efficiency of novel Docetaxel (Dtxl) loaded-[1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-carboxy(polyethylene glycol)]2000 stabilized-oleic acid coated hydroxyapatite nanoparticles and gained insights into the molecular mechanism of the apoptosis induced by these novel Dtxl-loaded nanoparticles. [J Control Release]

The rs10993994 Risk Allele for Prostate Cancer Results in Clinically Relevant Changes in Microseminoprotein-Beta Expression in Tissue and Urine
The data show that some high risk alleles discovered using genome-wide association studies produce phenotypic effects with potential clinical utility. [PLoS ONE]


Cancer Screening Among Patients With Advanced Cancer
The objective of this study was to evaluate the extent to which patients with advanced cancer continue to be screened for new cancers. [JAMA]

Differential Gene Expression in Benign Prostate Epithelium of Men with and without Prostate Cancer: Evidence for a Prostate Cancer Field Effect
Several malignancies are known to exhibit a “field-effect” whereby regions beyond tumor boundaries harbor histological or molecular changes that are associated with cancer. Researchers sought to determine if histologically benign prostate epithelium collected from men with prostate cancer exhibits features indicative of pre-malignancy or field effect. [Clin Cancer Res]


Fox Chase Launches Prostate REACH Initiative to “Reach Out” to Men at High-Risk for Prostate Cancer
Fox Chase Cancer Center has received a grant from The Philadelphia Foundation’s Lola E. Douglass and Margaret E. Demment funds to launch Prostate REACH, a new initiative aimed at making Fox Chase’s existing Prostate Cancer Risk Assessment Program more accessible to high-risk men through convenient community locations and patient navigation services. [Fox Chase Cancer Center Press Release]

Myriad Genetics’ PROLARIS Test Accurately Predicts Survival With Prostate Cancer
Myriad Genetics, Inc. announced that based on recent clinical validation, its newest molecular diagnostic product, PROLARIS(TM), accurately predicts survival with prostate cancer. [Myriad Genetics, Inc. Press Release]

Abiraterone Acetate Significantly Improved Overall Survival for Patients with Metastatic Advanced Prostate Cancer
Results from a pre-specified interim analysis of a randomized, placebo-controlled Phase III study, COU-AA-301, demonstrate that patients treated with the investigational agent abiraterone acetate plus low dose prednisone/prednisolone showed a significant improvement in overall survival compared to patients treated with prednisone/prednisolone plus placebo. [Johnson and Johnson Press Release]

Molecular Insight Pharmaceuticals Presents Positive Data From Clinical Studies Comparing Trofex(TM) and ProstaScint(R) for Detection of Metastatic Prostate Cancer
Molecular Insight Pharmaceuticals, Inc., presented positive data from Phase I clinical studies comparing Trofex(TM) (123I-MIP-1072), its lead molecular imaging candidate for the diagnosis and monitoring of metastatic prostate cancer, and ProstaScint(R) (111In-capromab pendetide), an imaging radiopharmaceutical for the visualization of metastatic prostate cancer. [Molecular Insight Pharmaceuticals, Inc. Press Release]


NIH Announces New Program to Accelerate Research Independence
The National Institutes of Health intends to invest approximately $60 million over the next five years in the NIH Director’s Early Independence Award program to help junior investigators leapfrog over traditional post-doctoral training and move into independent academic positions at U.S. institutions, directly upon completion of their graduate research degrees. [National Institutes of Health, United States]

NIH Launches Genotype-Tissue Expression Project
The National Institutes of Health (NIH) announced awards to support an initiative to understand how genetic variation may control gene activity and its relationship to disease. Launched as a pilot phase, the Genotype-Tissue Expression (GTEx) project will create a resource researchers can use to study inherited susceptibility to illness and will establish a tissue bank for future biological studies. [National Institutes of Health, United States]

FDA’s $25 Million Pitch for Improving Drug Regulation
The U.S. Food and Drug Administration (FDA) is pressing for a big funding boost for “regulatory science”- research that can help it evaluate new treatments better and faster. [Food and Drug Administration, United States]

FDA to Push for More Investment in Science
Health regulators plan to spend millions of dollars to step up their scientific prowess in a move that officials say will help quickly get new treatments to patients and protect the public against possible health threats. [Food and Drug Administration, United States]

FDA Issues Regulatory Science Report
The U.S. Food and Drug Administration unveiled a report outlining the agency’s plans to advance regulatory science through its Regulatory Science Initiative. [Food and Drug Administration, United States]

Plan to Develop a Genetic Testing Registry at the National Institutes of Health; Public Meeting; Request for Comments (FR Doc. 2010-25411) [National Institutes of Health, United States]

Center for Scientific Review; Amended Notice of Meeting (FR Doc. 2010-25171) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-25180) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-25185) [National Institutes of Health, United States]

EVENTS (Listed by Date)

American Association for Cancer Research (AACR) Translational Cancer Research for Basic Scientists
October 17-22, 2010
Boston, United States

6th Modern Drug Discovery & Development Summit (M3D)
October 20-22, 2010
San Francisco, United States

NEW Cancer Immunotherapy: A Long-Awaited Reality
October 21, 2010
New York, United States

American Institute for Cancer Research (AICR) 2010 Annual Cancer Research Conference
October 21-22, 2010
Washington, DC, United States

Frontiers in Tumour Progression
October 24-27, 2010
Madrid, Spain

Select Biosciences 3rd Annual Molecular Diagnostics World Congress
October 28-29, 2010
San Diego, United States

UAE Cancer Congress 2010
October 28-30, 2010
Dubai, United Arab Emirates

NEW 5th UK Cancer Stem Cell Symposium
November 2, 2010
London, United Kingdom

6th National Cancer Research Institute (NCRI) Conference
November 7-10, 2010
Liverpool, United Kingdom

9th Annual American Association for Cancer Research (AACR) International Conference: Frontiers in Cancer Prevention Research
November 7-10, 2010
Philadelphia, United States

22nd European Organization for Research and Treatment of Cancer (EORTC)-National Cancer Institute (NCI)-American Association for Cancer Research (AACR) Symposium: Molecular Targets and Cancer Therapeutics
November 16-19, 2010
Berlin, Germany

Cancer Pharmacogenetics: Personalizing Medicine
November 22-24, 2010
Madrid, Spain

NEW Tumor Immunology: Basic and Clinical Advances
November 30-December 3, 2010
Miami, United Sates

NEW 5th Annual Stem Cell Meeting on the Mesa
December 7, 2010
La Jolla, United States

11th Annual Meeting of the Society of Urologic Oncology (SUO) Extraordinary Opportunities for Discovery
December 8-9, 2010
Bethesda, United States

NEW Targeting PI3K/mTOR Signaling in Cancer
February 24-27, 2011
San Francisco, United Sates

American Association for Cancer Research (AACR) Stem Cells, Development, and Cancer
March 3-6, 2011
Vancouver, Canada

MENA Oncology Conference
March 11-12, 2010
Cairo, Egypt

The 6th International Conference on Oncolytic Viruses as Cancer Therapeutics
March 16-19, 2011
Las Vegas, United States

American Association for Cancer Research (AACR) 102nd Annual Meeting 2011
April 2-6, 2011
Orlando, United States

International Society for Stem Cell Research (ISSCR) 9th Annual Meeting
June 15-18, 2011
Toronto, Canada

National Cancer Institute (NCI) Cancer Research Imaging Camp
June 19-24, 2011
St. Louis, United States

4th Annual Advances in Biodetection & Biosensors Conference and Exhibition
June 30-July 1, 2011
Hamburg, Germany

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


Clean Room Team Leader – Cellular Therapy (Cell Medica Limited)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Prostate Cell News at no cost.
Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives  |  Events  |  Subscribe  |  Contact Us